Briakinumab - CISMeF

Preferred Label : Briakinumab;

NCIt synonyms : Kriakinumab; Immunoglobulin G1, Anti-(Human Interleukin-12 Subunit Beta (IL-12 Subunit P40, CLMF P40 or NKSF2)); Human Monoclonal Gamma-1 Heavy Chain (218-216')-Disulfide with Human Monoclonal Gamma Light Chain, Dimer (224-224'':227-227'')-Bisdisulfide;

NCIt definition : A human monoclonal antibody directed against the human interleukins 12 (IL-12) and 23 (IL-23), with immunomodulating activity. Briakinumab binds to both IL-12 and IL-23, which prevents IL-12- and IL-23-mediated signaling. This may suppress immune responses mediated by these interleukins. The cytokines IL-12 and IL-23 play an important role during inflammation.;

NCIt note : Market application withdrawn in Jan. 2011;

UNII : 978I8M0P8X;

CAS number : 339308-60-0;

Drug name : Ozespa;

Molecule name : WAY-165772; A-796874.0; J-695; LU-415977; ABT-874; BSF-415977;

Details

Origin ID

C95321;

UMLS CUI

C2744325;

Automatic exact mappings (from CISMeF team)
- Briakinumab [ICD-11 Extension code]
Currated CISMeF NLP mapping
- briakinumab [MeSH concept]
- briakinumab [MeSH Supplementary Concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- briakinumab [ATC Code]
- briakinumab [MeSH concept]
- briakinumab [MeSH Supplementary Concept]
Validated automatic mappings to BTNT
- briakinumab [ATC Code]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients